Type I interferon in the pathogenesis of lupus

Journal of Immunology

Volumn 192, Issue 12, 2014, Pages 5459-5468

  Crow, Mary K ^a,b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON ANTIBODY; ANIFROLUMAB; AUTOANTIBODY; AUTOPHAGY PROTEIN 5; BETA INTERFERON; BORTEZOMIB; GAMMA INTERFERON; GLUCOCORTICOID; INTERFERON; INTERFERON 1 RECEPTOR; INTERFERON ANTIBODY; INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 5; RONTALIZUMAB; SIFALIMUMAB; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; CYTOKINE PRODUCTION; DRUG TARGETING; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; IFN I INDUCED GENE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INNATE IMMUNITY; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC; TOLL-LIKE RECEPTORS;

EID: 84902203558     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002795     Document Type: Review

References (130)

1. Crow, M. K. 2009. Developments in the clinical understanding of lupus. Arthritis Res. Ther. 11:245.
2. Kono, D. H., R. Baccala, and A. N. Theofilopoulos. 2013. TLRs and interferons: a central paradigm in autoimmunity. Curr. Opin. Immunol. 25:720-727.
3. Arbuckle, M. R., M. T. McClain, M. V. Rubertone, R. H. Scofield, G. J. Dennis, J. A. James, and J. B. Harley. 2003. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349:1526-1533.
4. Lerner, E. A., M. R. Lerner, J. A. Hardin, C. A. Janeway, Jr., and J. A. Steitz. 1982. Deciphering the mysteries of RNA-containing lupus antigens. Arthritis Rheum. 25:761-766.
5. Takeuchi, T., T. Abe, J. Koide, O. Hosono, C. Morimoto, and M. Homma. 1984. Cellular mechanism of DNA-specific antibody synthesis by lymphocytes from systemic lupus erythematosus patients. Arthritis Rheum. 27:766-773.
6. Furie, R., M. Petri, O. Zamani, R. Cervera, D. J. Wallace, D. Tegzová, J. Sanchez-Guerrero, A. Schwarting, J. T. Merrill, W. W. Chatham, et al; BLISS-76 Study Group. 2011. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63:3918-3930.
7. Witt, M., M. Grunke, F. Proft, M. Baeuerle, M. Aringer, G. Burmester, G. Chehab, C. Fiehn, R. Fischer-Betz, M. Fleck, et al; German Registry of Autoimmune Diseases (GRAID) Investigators. 2013. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Lupus 22:1142-1149.
8. Wofsy, D., J. L. Hillson, and B. Diamond. 2012. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 64:3660-3665.
9. Hooks, J. J., H. M. Moutsopoulos, S. A. Geis, N. I. Stahl, J. L. Decker, and A. L. Notkins. 1979. Immune interferon in the circulation of patients with autoimmune disease. N. Engl. J. Med. 301:5-8.
10. Kopp, E. B., and R. Medzhitov. 1999. The Toll-receptor family and control of innate immunity. Curr. Opin. Immunol. 11:13-18.
11. Barbalat, R., S. E. Ewald, M. L. Mouchess, and G. M. Barton. 2011. Nucleic acid recognition by the innate immune system. Annu. Rev. Immunol. 29:185-214.
12. Unterholzner, L. 2013. The interferon response to intracellular DNA: why so many receptors? Immunobiology 218:1312-1321.
13. Crow, M. K., and K. A. Kirou. 2004. Interferon-alpha in systemic lupus erythematosus. Curr. Opin. Rheumatol. 16:541-547.
14. Rönnblom, L., G. V. Alm, and M. L. Eloranta. 2011. The type I interferon system in the development of lupus. Semin. Immunol. 23:113-121.
15. Steinberg, A. D., S. Baron, and N. Talal. 1969. The pathogenesis of autoimmunity in New Zealand mice, I. Induction of antinucleic acid antibodies by polyinosinicpolycytidylic acid. Proc. Natl. Acad. Sci. USA 63:1102-1107.
16. Gota, C., and L. Calabrese. 2003. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 36:511-518.
17. Baechler, E. C., F. M. Batliwalla, G. Karypis, P. M. Gaffney, W. A. Ortmann, K. J. Espe, K. B. Shark, W. J. Grande, K. M. Hughes, V. Kapur, et al. 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100:2610-2615.
18. Bennett, L., A. K. Palucka, E. Arce, V. Cantrell, J. Borvak, J. Banchereau, and V. Pascual. 2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197:711-723.
19. Crow, M. K., K. A. Kirou, and J. Wohlgemuth. 2003. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 36:481-490.
20. Crow, M. K., and J. Wohlgemuth. 2003. Microarray analysis of gene expression in lupus. Arthritis Res. Ther. 5:279-287.
21. Han, G. M., S. L. Chen, N. Shen, S. Ye, C. D. Bao, and Y. Y. Gu. 2003. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun. 4:177-186.
22. Absher, D. M., X. Li, L. L. Waite, A. Gibson, K. Roberts, J. Edberg, W. W. Chatham, and R. P. Kimberly. 2013. Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations. PLoS Genet. 9:e1003678.
23. Coit, P., M. Jeffries, N. Altorok, M. G. Dozmorov, K. A. Koelsch, J. D. Wren, J. T. Merrill, W. J. McCune, and A. H. Sawalha. 2013. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naïve CD4+ T cells from lupus patients. J. Autoimmun. 43:78-84.
24. Kirou, K. A., C. Lee, S. George, K. Louca, I. G. Papagiannis, M. G. Peterson, N. Ly, R. N. Woodward, K. E. Fry, A. Y. Lau, et al. 2004. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum. 50:3958-3967.
25. Yao, Y., B. W. Higgs, C. Morehouse, M. De Los Reyes, W. Trigona, P. Brohawn, W. White, J. Zhang, B. White, A. J. Coyle, et al. 2009. Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus. Hum. Genomics Proteomics 2009:2009.
26. Hua, J., K. Kirou, C. Lee, and M. K. Crow. 2006. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 54:1906-1916.
27. Becker, A. M., K. H. Dao, B. K. Han, R. Kornu, S. Lakhanpal, A. B. Mobley, Q. Z. Li, Y. Lian, T. Wu, A. M. Reimold, et al. 2013. SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature. PLoS ONE 8:e67003.
28. Feng, X., H. Wu, J. M. Grossman, P. Hanvivadhanakul, J. D. Fitz Gerald, G. S. Park, X. Dong, W. Chen, M. H. Kim, H. H. Weng, et al. 2006. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 54:2951-2962.
29. Chaussabel, D., C. Quinn, J. Shen, P. Patel, C. Glaser, N. Baldwin, D. Stichweh, D. Blankenship, L. Li, I. Munagala, et al. 2008. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29:150-164.
30. Petri, M., S. Singh, H. Tesfasyone, R. Dedrick, K. Fry, P. Lal, G. Williams, J. Bauer, P. Gregersen, T. Behrens, and E. Baechler. 2009. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 18:980-989.
31. Landolt-Marticorena, C., G. Bonventi, A. Lubovich, C. Ferguson, T. Unnithan, J. Su, D. D. Gladman, M. Urowitz, P. R. Fortin, and J. Wither. 2009. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann. Rheum. Dis. 68:1440-1446.
32. Chiche, L., N. Jourde-Chiche, V. Pascual, and D. Chaussabel. 2013. Current perspectives on systems immunology approaches to rheumatic diseases. Arthritis Rheum. 65:1407-1417.
33. Der, S. D., A. Zhou, B. R. Williams, and R. H. Silverman. 1998. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl. Acad. Sci. USA 95:15623-15628.
34. Waddell, S. J., S. J. Popper, K. H. Rubins, M. J. Griffiths, P. O. Brown, M. Levin, and D. A. Relman. 2010. Dissecting interferon-induced transcriptional programs in human peripheral blood cells. PLoS ONE 5:e9753.
35. Hall, J. C., L. Casciola-Rosen, A. E. Berger, E. K. Kapsogeorgou, C. Cheadle, A. G. Tzioufas, A. N. Baer, and A. Rosen. 2012. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc. Natl. Acad. Sci. USA 109:17609-17614.
36. Wu, Q., Q. Yang, E. Lourenco, H. Sun, and Y. Zhang. 2011. Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity. Arthritis Res. Ther. 13:R88.
37. Morimoto, A. M., D. T. Flesher, J. Yang, K. Wolslegel, X. Wang, A. Brady, A. R. Abbas, V. Quarmby, E. Wakshull, B. Richardson, et al. 2011. Association of endogenous anti-interferon - a autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 63:2407-2415.
38. Greenberg, S. A., B. W. Higgs, C. Morehouse, R. J. Walsh, S. W. Kong, P. Brohawn, W. Zhu, A. Amato, M. Salajegheh, B. White, et al. 2012. Relationship between disease activity and type 1 interferon- and other cytokineinducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun. 13:207-213.
39. Emamian, E. S., J. M. Leon, C. J. Lessard, M. Grandits, E. C. Baechler, P. M. Gaffney, B. Segal, N. L. Rhodus, and K. L. Moser. 2009. Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun. 10:285-296.
40. Higgs, B. W., Z. Liu, B. White, W. Zhu, W. I. White, C. Morehouse, P. Brohawn, P. A. Kiener, L. Richman, D. Fiorentino, et al. 2011. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann. Rheum. Dis. 70:2029-2036.
41. Hardy, G. A., S. Sieg, B. Rodriguez, D. Anthony, R. Asaad, W. Jiang, J. Mudd, T. Schacker, N. T. Funderburg, H. A. Pilch-Cooper, et al. 2013. Interferon - a is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. PLoS ONE 8:e56527.
42. Teijaro, J. R., C. Ng, A. M. Lee, B. M. Sullivan, K. C. Sheehan, M. Welch, R. D. Schreiber, J. C. De La Torre, and M. B. Oldstone. 2013. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340:207-211.
43. Wilson, E. B., D. H. Yamada, H. Elsaesser, J. Herskovitz, J. Deng, G. Cheng, B. J. Aronow, C. L. Karp, and D. G. Brooks. 2013. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340:202-207.
44. Deng, Y., and B. P. Tsao. 2010. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat. Rev. Rheumatol. 6:683-692.
45. Niewold, T. B., J. Hua, T. J. Lehman, J. B. Harley, and M. K. Crow. 2007. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 8:492-502.
46. Dai, X., R. G. James, T. Habib, S. Singh, S. Jackson, S. Khim, R. T. Moon, D. Liggitt, A. Wolf-Yadlin, J. H. Buckner, and D. J. Rawlings. 2013. A diseaseassociated PTPN22 variant promotes systemic autoimmunity in murine models. J. Clin. Invest. 123:2024-2036.
47. Li, Q. Z., J. Zhou, R. Yang, M. Yan, Q. Ye, K. Liu, S. Liu, X. Shao, L. Li, X. J. Zhou, et al. 2009. The lupus-susceptibility gene kallikrein downmodulates antibody-mediated glomerulonephritis. Genes Immun. 10:503-508.
48. Crow, Y. J., and J. Rehwinkel. 2009. Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity. Hum. Mol. Genet. 18 (R2):R130-R136.
49. Lee-Kirsch, M. A., C. Wolf, and C. Günther. 2014. Aicardi-Goutières syndrome: a model disease for systemic autoimmunity. Clin. Exp. Immunol. 175:17-24.
50. Namjou, B., P. H. Kothari, J. A. Kelly, S. B. Glenn, J. O. Ojwang, A. Adler, M. E. Alarcón-Riquelme, C. J. Gallant, S. A. Boackle, L. A. Criswell, et al. 2011. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 12:270-279.
51. Rice, G. I., G. M. Forte, M. Szynkiewicz, D. S. Chase, A. Aeby, M. S. Abdel-Hamid, S. Ackroyd, R. Allcock, K. M. Bailey, U. Balottin, et al. 2013. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol. 12:1159-1169.
52. Troedson, C., M. Wong, J. Dalby-Payne, M. Wilson, M. Dexter, G. I. Rice, Y. J. Crow, and R. C. Dale. 2013. Systemic lupus erythematosus due to C1q deficiency with progressive encephalopathy, intracranial calcification and acquired moyamoya cerebral vasculopathy. Lupus 22:639-643.
53. Lazear, H. M., A. Lancaster, C. Wilkins, M. S. Suthar, A. Huang, S. C. Vick, L. Clepper, L. Thackray, M. M. Brassil, H. W. Virgin, et al. 2013. IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog. 9:e1003118.
54. Niewold, T. B., J. A. Kelly, M. H. Flesch, L. R. Espinoza, J. B. Harley, and M. K. Crow. 2008. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 58:2481-2487.
55. Barrat, F. J., T. Meeker, J. Gregorio, J. H. Chan, S. Uematsu, S. Akira, B. Chang, O. Duramad, and R. L. Coffman. 2005. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202:1131-1139.
56. Lövgren, T., M. L. Eloranta, B. Kastner, M. Wahren-Herlenius, G. V. Alm, and L. Rönnblom. 2006. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA. Arthritis Rheum. 54:1917-1927.
57. Means, T. K., E. Latz, F. Hayashi, M. R. Murali, D. T. Golenbock, and A. D. Luster. 2005. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 115:407-417.
58. Kelly, K. M., H. Zhuang, D. C. Nacionales, P. O. Scumpia, R. Lyons, J. Akaogi, P. Lee, B. Williams, M. Yamamoto, S. Akira, et al. 2006. "Endogenous adjuvant" activity of the RNA components of lupus autoantigens Sm/RNP and Ro 60. Arthritis Rheum. 54:1557-1567.
59. Cherian, T. S., S. N. Kariuki, B. S. Franek, J. P. Buyon, R. M. Clancy, and T. B. Niewold. 2012. Brief Report: IRF5 systemic lupus erythematosus risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in mothers of children with neonatal lupus. Arthritis Rheum. 64:3383-3387.
60. Robinson, T., S. N. Kariuki, B. S. Franek, M. Kumabe, A. A. Kumar, M. Badaracco, R. A. Mikolaitis, G. Guerrero, T. O. Utset, B. E. Drevlow, et al. 2011. Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-a and serologic autoimmunity in lupus patients. J. Immunol. 187:1298-1303.
61. Pothlichet, J., T. B. Niewold, D. Vitour, B. Solhonne, M. K. Crow, and M. Si-Tahar. 2011. A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients. EMBO Mol. Med. 3:142-152.
62. Cunninghame Graham, D. S., D. L. Morris, T. R. Bhangale, L. A. Criswell, A. C. Syvänen, L. Rönnblom, T. W. Behrens, R. R. Graham, and T. J. Vyse. 2011. Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet. 7:e1002341.
63. Kariuki, S. N., K. A. Kirou, E. J. MacDermott, L. Barillas-Arias, M. K. Crow, and T. B. Niewold. 2009. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J. Immunol. 182:34-38.
64. Kariuki, S. N., J. G. Moore, K. A. Kirou, M. K. Crow, T. O. Utset, and T. B. Niewold. 2009. Age- and gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus. Genes Immun. 10:487-494.
65. Gehrke, N., C. Mertens, T. Zillinger, J. Wenzel, T. Bald, S. Zahn, T. Tüting, G. Hartmann, and W. Barchet. 2013. Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. Immunity 39:482-495.
66. Hirai, M., N. Kadowaki, T. Kitawaki, H. Fujita, A. Takaori-Kondo, R. Fukui, K. Miyake, T. Maeda, S. Kamihira, Y. Miyachi, and T. Uchiyama. 2011. Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis. Blood 117:500-509.
67. Farkas, L., K. Beiske, F. Lund-Johansen, P. Brandtzaeg, and F. L. Jahnsen. 2001. Plasmacytoid dendritic cells (natural interferon-alpha/beta- producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol. 159:237-243.
68. Denny, M. F., S. Yalavarthi, W. Zhao, S. G. Thacker, M. Anderson, A. R. Sandy, W. J. McCune, and M. J. Kaplan. 2010. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J. Immunol. 184:3284-3297.
69. Kaplan, M. J. 2013. Role of neutrophils in systemic autoimmune diseases. Arthritis Res. Ther. 15:219.
70. Lindau, D., J. Mussard, A. Rabsteyn, M. Ribon, I. Kötter, A. Igney, G. J. Adema, M. C. Boissier, H. G. Rammensee, and P. Decker. 2013. TLR9 independent interferon a production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen. Ann. Rheum. Dis. DOI: 10.1136/annrheumdis-2012-203041.
71. Palanichamy, A., J. W. Bauer, S. Yalavarthi, N. Meednu, J. Barnard, T. Owen, C. Cistrone, A. Bird, A. Rabinovich, S. Nevarez, et al. 2014. Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus. J. Immunol. 192:906-918.
72. Tian, J., A. M. Avalos, S. Y. Mao, B. Chen, K. Senthil, H. Wu, P. Parroche, S. Drabic, D. Golenbock, C. Sirois, et al. 2007. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8:487-496.
73. Chamilos, G., J. Gregorio, S. Meller, R. Lande, D. P. Kontoyiannis, R. L. Modlin, and M. Gilliet. 2012. Cytosolic sensing of extracellular self-DNA transported into monocytes by the antimicrobial peptide LL37. Blood 120:3699-3707.
74. Kirou, K. A., C. Lee, S. George, K. Louca, M. G. Peterson, and M. K. Crow. 2005. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52:1491-1503.
75. Henault, J., J. Martinez, J. M. Riggs, J. Tian, P. Mehta, L. Clarke, M. Sasai, E. Latz, M. M. Brinkmann, A. Iwasaki, et al. 2012. Noncanonical autophagy is required for type I interferon secretion in response to DNA-immune complexes. Immunity 37:986-997.
76. Zhou, X. J., X. L. Lu, J. C. Lv, H. Z. Yang, L. X. Qin, M. H. Zhao, Y. Su, Z. G. Li, and H. Zhang. 2011. Genetic association of PRDM1-ATG5 intergenic region and autophagy with systemic lupus erythematosus in a Chinese population. Ann. Rheum. Dis. 70:1330-1337.
77. Christensen, S. R., J. Shupe, K. Nickerson, M. Kashgarian, R. A. Flavell, and M. J. Shlomchik. 2006. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25:417-428.
78. Blander, J. M., and R. Medzhitov. 2006. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440:808-812.
79. Green, N. M., and A. Marshak-Rothstein. 2011. Toll-like receptor driven B cell activation in the induction of systemic autoimmunity. Semin. Immunol. 23:106-112.
80. Koh, Y. T., J. C. Scatizzi, J. D. Gahan, B. R. Lawson, R. Baccala, K. M. Pollard, B. A. Beutler, A. N. Theofilopoulos, and D. H. Kono. 2013. Role of nucleic acidsensing TLRs in diverse autoantibody specificities and anti-nuclear antibodyproducing B cells. J. Immunol. 190:4982-4990.
81. Walsh, E. R., P. Pisitkun, E. Voynova, J. A. Deane, B. L. Scott, R. R. Caspi, and S. Bolland. 2012. Dual signaling by innate and adaptive immune receptors is required for TLR7-induced B-cell-mediated autoimmunity. Proc. Natl. Acad. Sci. USA 109:16276-16281.
82. Gall, A., P. Treuting, K. B. Elkon, Y. M. Loo, M. Gale, Jr., G. N. Barber, and D. B. Stetson. 2012. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 36:120-131.
83. Yang, Y. G., T. Lindahl, and D. E. Barnes. 2007. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 131:873-886.
84. Behrendt, R., T. Schumann, A. Gerbaulet, L. A. Nguyen, N. Schubert, D. Alexopoulou, U. Berka, S. Lienenklaus, K. Peschke, K. Gibbert, et al. 2013. Mouse SAMHD1 has antiretroviral activity and suppresses a spontaneous cellintrinsic antiviral response. Cell. Rep. 4:689-696.
85. Stetson, D. B., J. S. Ko, T. Heidmann, and R. Medzhitov. 2008. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134:587-598.
86. Zhao, K., J. Du, X. Han, J. L. Goodier, P. Li, X. Zhou, W. Wei, S. L. Evans, L. Li, W. Zhang, et al. 2013. Modulation of LINE-1 and Alu/SVA retrotransposition by Aicardi-Goutières syndrome-related SAMHD1. Cell. Rep. 4:1108-1115.
87. Crow, M. K. 2010. Long interspersed nuclear elements (LINE-1): potential triggers of systemic autoimmune disease. Autoimmunity 43:7-16.
88. Takaoka, A., Z. Wang, M. K. Choi, H. Yanai, H. Negishi, T. Ban, Y. Lu, M. Miyagishi, T. Kodama, K. Honda, et al. 2007. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448:501-505.
89. Kato, H., O. Takeuchi, E. Mikamo-Satoh, R. Hirai, T. Kawai, K. Matsushita, A. Hiiragi, T. S. Dermody, T. Fujita, and S. Akira. 2008. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 205:1601-1610.
90. Barber, G. N. 2014. STING-dependent cytosolic DNA sensing pathways. Trends Immunol. 35:88-93.
91. Sun, L., J. Wu, F. Du, X. Chen, and Z. J. Chen. 2013. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339:786-791.
92. Ablasser, A., M. Goldeck, T. Cavlar, T. Deimling, G. Witte, I. Röhl, K. P. Hopfner, J. Ludwig, and V. Hornung. 2013. cGAS produces a 29-59-linked cyclic dinucleotide second messenger that activates STING. Nature 498:380-384.
93. Zhang, X., T. W. Brann, M. Zhou, J. Yang, R. M. Oguariri, K. B. Lidie, H. Imamichi, D. W. Huang, R. A. Lempicki, M. W. Baseler, et al. 2011. Cutting edge: Ku70 is a novel cytosolic DNA sensor that induces type III rather than type I IFN. J. Immunol. 186:4541-4545.
94. Sharma, S., B. R. Ten Oever, N. Grandvaux, G. P. Zhou, R. Lin, and J. Hiscott. 2003. Triggering the interferon antiviral response through an IKK-related pathway. Science 300:1148-1151.
95. Hasan, M., J. Koch, D. Rakheja, A. K. Pattnaik, J. Brugarolas, I. Dozmorov, B. Levine, E. K. Wakeland, M. A. Lee-Kirsch, and N. Yan. 2013. Trex1 regulates lysosomal biogenesis and interferon-independent activation of antiviral genes. Nat. Immunol. 14:61-71.
96. Ma, Z., R. Moore, X. Xu, and G. N. Barber. 2013. DDX24 negatively regulates cytosolic RNA-mediated innate immune signaling. PLoS Pathog. 9:e1003721.
97. Lande, R., D. Ganguly, V. Facchinetti, L. Frasca, C. Conrad, J. Gregorio, S. Meller, G. Chamilos, R. Sebasigari, V. Riccieri, et al. 2011. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 3:73ra19.
98. Garcia-Romo, G. S., S. Caielli, B. Vega, J. Connolly, F. Allantaz, Z. Xu, M. Punaro, J. Baisch, C. Guiducci, R. L. Coffman, et al. 2011. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3:73ra20.
99. Campbell, A. M., M. Kashgarian, and M. J. Shlomchik. 2012. NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus. Sci. Transl. Med. 4:157ra141.
100. Kahlenberg, J. M., C. Carmona-Rivera, C. K. Smith, and M. J. Kaplan. 2013. Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J. Immunol. 190:1217-1226.
101. Ries, M., P. Schuster, S. Thomann, N. Donhauser, J. Vollmer, and B. Schmidt. 2013. Identification of novel oligonucleotides from mitochondrial DNA that spontaneously induce plasmacytoid dendritic cell activation. J. Leukoc. Biol. 94:123-135.
102. Feng, D., and B. J. Barnes. 2013. Bioinformatics analysis of the factors controlling type I IFN gene expression in autoimmune disease and virus-induced immunity. Front. Immunol. 4:291.
103. González-Navajas, J. M., J. Lee, M. David, and E. Raz. 2012. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 12:125-135.
104. Pace, L., S. Vitale, B. Dettori, C. Palombi, V. La Sorsa, F. Belardelli, E. Proietti, and G. Doria. 2010. APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions. J. Immunol. 184:5969-5979.
105. Blanco, P., A. K. Palucka, M. Gill, V. Pascual, and J. Banchereau. 2001. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294:1540-1543.
106. Ittah, M., C. Miceli-Richard, J. Eric Gottenberg, F. Lavie, T. Lazure, N. Ba, J. Sellam, C. Lepajolec, and X. Mariette. 2006. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome. Arthritis Res. Ther. 8:R51.
107. Nzeusseu Toukap, A., C. Galant, I. Theate, A. L. Maudoux, R. J. Lories, F. A. Houssiau, and B. R. Lauwerys. 2007. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum. 56:1579-1588.
108. Coelho, L. F., G. Magno De Freitas Almeida, F. J. Mennechet, A. Blangy, and G. Uzé. 2005. Interferon-alpha and -beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. Proc. Natl. Acad. Sci. USA 102:11917-11922.
109. Tucci, M., C. Quatraro, L. Lombardi, C. Pellegrino, F. Dammacco, and F. Silvestris. 2008. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum. 58:251-262.
110. Liu, Z., R. Bethunaickan, W. Huang, U. Lodhi, I. Solano, M. P. Madaio, and A. Davidson. 2011. Interferon - a accelerates murine systemic lupus erythematosus in a T cell-dependent manner. Arthritis Rheum. 63:219-229.
111. Migliorini, A., M. L. Angelotti, S. R. Mulay, O. O. Kulkarni, J. Demleitner, A. Dietrich, C. Sagrinati, L. Ballerini, A. Peired, S. J. Shankland, et al. 2013. The antiviral cytokines IFN-a and IFN-b modulate parietal epithelial cells and promote podocyte loss: implications for IFN toxicity, viral glomerulonephritis, and glomerular regeneration. Am. J. Pathol. 183:431-440.
112. Bauer, J. W., M. Petri, F. M. Batliwalla, T. Koeuth, J. Wilson, C. Slattery, A. Panoskaltsis-Mortari, P. K. Gregersen, T. W. Behrens, and E. C. Baechler. 2009. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 60:3098-3107.
113. Li, J., Q. Fu, H. Cui, B. Qu, W. Pan, N. Shen, and C. Bao. 2011. Interferon - a priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-a and atherosclerosis in lupus. Arthritis Rheum. 63:492-502.
114. Somers, E. C., W. Zhao, E. E. Lewis, L. Wang, J. J. Wing, B. Sundaram, E. A. Kazerooni, W. J. McCune, and M. J. Kaplan. 2012. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS ONE 7:e37000.
115. Pulliero, A., B. Marengo, M. Longobardi, E. Fazzi, S. Orcesi, I. Olivieri, C. Cereda, C. Domenicotti, U. Balottin, and A. Izzotti. 2013. Inhibition of the demyelinating properties of Aicardi-Goutières syndrome lymphocytes by cathepsin D silencing. Biochem. Biophys. Res. Commun. 430:957-962.
116. Kirou, K. A., and E. Gkrouzman. 2013. Anti-interferon alpha treatment in SLE. Clin. Immunol. 148:303-312.
117. Stohl, W. 2013. Future prospects in biologic therapy for systemic lupus erythematosus. Nat. Rev. Rheumatol. 9:705-720.
118. Yao, Y., L. Richman, B. W. Higgs, C. A. Morehouse, M. De Los Reyes, P. Brohawn, J. Zhang, B. White, A. J. Coyle, P. A. Kiener, and B. Jallal. 2009. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 60:1785-1796.
119. Merrill, J. T., D. J. Wallace, M. Petri, K. A. Kirou, Y. Yao, W. I. White, G. Robbie, R. Levin, S. M. Berney, V. Chindalore, et al; Lupus Interferon Skin Activity (LISA) Study Investigators. 2011. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon a monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann. Rheum. Dis. 70:1905-1913.
120. McBride, J. M., J. Jiang, A. R. Abbas, A. Morimoto, J. Li, R. Maciuca, M. Townsend, D. J. Wallace, W. P. Kennedy, and J. Drappa. 2012. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 64:3666-3676.
121. Bissonnette, R., K. Papp, C. Maari, Y. Yao, G. Robbie, W. I. White, C. Le, and B. White. 2010. A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. J. Am. Acad. Dermatol. 62:427-436.
122. Lauwerys, B. R., E. Hachulla, F. Spertini, E. Lazaro, C. Jorgensen, X. Mariette, E. Haelterman, G. Grouard-Vogel, B. Fanget, O. Dhellin, et al. 2013. Downregulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon a-kinoid. Arthritis Rheum. 65:447-456.
123. Baccala, R., R. Gonzalez-Quintial, R. D. Schreiber, B. R. Lawson, D. H. Kono, and A. N. Theofilopoulos. 2012. Anti-IFN-a/b receptor antibody treatment ameliorates disease in lupus-predisposed mice. J. Immunol. 189:5976-5984.
124. Wang, B., B. W. Higgs, L. Chang, I. Vainshtein, Z. Liu, K. Streicher, M. Liang, W. I. White, S. Yoo, L. Richman, et al. 2013. Pharmacogenomics and translational simulations to bridge indications for an anti-interferon - a receptor antibody. Clin. Pharmacol. Ther. 93:483-492.
125. Sun, X., A. Wiedeman, N. Agrawal, T. H. Teal, L. Tanaka, K. L. Hudkins, C. E. Alpers, S. Bolland, M. B. Buechler, J. A. Hamerman, et al. 2013. Increased ribonuclease expression reduces inflammation and prolongs survival in TLR7 transgenic mice. J. Immunol. 190:2536-2543.
126. Barrat, F. J., and R. L. Coffman. 2008. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol. Rev. 223:271-283.
127. Kandimalla, E. R., L. Bhagat, D. Wang, D. Yu, T. Sullivan, N. La Monica, and S. Agrawal. 2013. Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res. 41:3947-3961.
128. Sacre, K., L. A. Criswell, and J. M. McCune. 2012. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res. Ther. 14:R155.
129. Guiducci, C., C. Ghirelli, M. A. Marloie-Provost, T. Matray, R. L. Coffman, Y. J. Liu, F. J. Barrat, and V. Soumelis. 2008. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J. Exp. Med. 205:315-322.
130. Wang, S., N. Yang, L. Zhang, B. Huang, H. Tan, Y. Liang, Y. Li, and X. Yu. 2010. Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice. Lupus 19:1171-1180